The biopharma industry has reached a critical inflection point. As it enters new scientific frontiers, it is simultaneously faced with increased budgetary pressures, looming patent cliffs, and—in the U.S.—structural distortions and renewed attempts to implement "Most Favored Nation" price setting. These dynamics could radically shift global leadership and patient access. This panel explores our industry's standing in a global economy where international competitors are rapidly scaling innovation and attracting capital. It will examine the U.S.’s future-readiness and discuss how to better establish biopharma’s vital role as a strategic national asset—essential for medical progress, economic strength, national security, and preparedness. Finally, the group will discuss proactive public policy ideas to move beyond defensive measures and solidify the U.S. position as a global leader.